Feb 2 (Reuters) - Medexus Pharmaceuticals Inc MDP.V :
* MEDEXUS PHARMACEUTICALS - CO, U.S. UNIT ENTERED INTO COMMERCIALIZATION & SUPPLY AGREEMENT WITH MEDAC
* MEDEXUS PHARMACEUTICALS - MEDAC HAS GRANTED MEDEXUS PHARMA EXCLUSIVE LICENSE TO COMMERCIALIZE TREOSULFAN IN U.S.
* MEDEXUS PHARMACEUTICALS - PDUFA DATE TO REVIEW NDA IN RESPECT OF TREOSULFAN BY FDA HAS BEEN SCHEDULED FOR AUGUST 2021
* MEDEXUS PHARMACEUTICALS INC - UPON ENTERING INTO LICENSE AGREEMENT, MEDEXUS PHARMA PAID MEDAC A NON-REFUNDABLE UPFRONT PAYMENT OF U.S. $5 MILLION
* MEDEXUS PHARMACEUTICALS - UNDER TERMS, MEDEXUS PHARMA TO PAY MEDAC UP TO $55 MILLION IN NON-REFUNDABLE REGULATORY MILESTONE PAYMENTS
* MEDEXUS PHARMACEUTICALS - UNDER TERMS, MEDEXUS PHARMA TO PAY MEDAC UP TO $40 MILLION IN NON-REFUNDABLE SALES MILESTONE PAYMENTS
* MEDEXUS PHARMACEUTICALS - MEDEXUS PHARMA TO PAY MEDAC A LOW SINGLE-DIGIT ROYALTY ON ITS NET SALES OF TREOSULFAN IN U.S.